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Introduction
One of the critical host defense strategies after infection is
to withhold iron from the invading pathogen by redistribution
of iron out of the circulation into macrophages and decrease
of iron absorption by enterocytes.1,2 This inflammation-associ-
ated reaction is mediated primarily by the hepatocellular pep-
tide hormone hepcidin.3,4 Hepatic hepcidin production is
under the control of various physiological stimuli, i.e it is
down-regulated by low body iron status and erythropoietic
activity and increased by pro-inflammation cytokines, partic-
ularly interleukin -6 (IL-6).5,6
Patients with HFE-gene related (C282Y-homozygous) hered-
itary hemochromatosis (HH) have an impaired hepcidin gene
expression with decreased, although not uniformly low, serum
hepcidin levels.7 Experiments in HFE-knock out (KO) mice
show that, in spite of this positive regulatory action of HFE-
protein on basal hepcidin levels, HFE-protein is not required for
hepcidin upregulation during inflammation.5,8,9 One study,
however, showed a blunted hepcidin response to inflammato-
ry stimuli in the KO-mice.10 Thus, with respect to hepcidin reg-
ulation at least two distinguishable pathways are operational:
one which is HFE-protein dependent and one engaged after
pro-inflammatory stimuli. To the best of our knowledge, these
mouse data have not yet been confirmed by observations in
humans. Here we describe the temporal relationships of serum
hepcidin, serum iron and inflammatory cytokines, in a C282Y
homozygous HH patient who was treated for an auto-inflam-
matory condition, i.e. variant Schnitzler’s syndrome,11 with the
potent anti-inflammatory cytokine interleukin-1 receptor
antagonist (anakinra).12 We demonstrate the existence of an
HFE-independent cytokine-hepcidin axis in the development
of hypoferremia and anemia of inflammation. Our observa-
tions further suggest that chronic inflammation countermands
iron accumulation in C282Y-homozygotes.
Case description
The patient, a 53-year old man, started having complaints in
1991, at the age of 36 years. From that time he experienced
periodically malaise, myalgia, spiking fever, arthralgia, painful
swelling and redness of eye lids. At first examination his
spleen was slightly enlarged and laboratory analysis showed a
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It is currently unknown if the increase of the hepatic iron
regulatory hormone hepcidin during inflammation in man
depends on an intact HFE-protein. Here we describe the
temporal relationship of serum hepcidin, serum iron and
cytokines in a patient with HFE-related (C282Y homozy-
gous) hereditary hemochromatosis who was treated for an
auto-inflammatory condition, i.e. variant Schnitzler’s syn-
drome, with the potent anti-inflammatory cytokine inter-
leukin-1 receptor antagonist (IL-1ra, anakinra). The patient
had bouts of fever with peaking serum IL-6 concentrations
followed by peaking serum hepcidin levels, while serum
iron was low. Upon treatment, these peaks disappeared
and hepcidin levels became non-detectable, consistent
with HFE deficiency. In conclusion, this in vivo human
model: i) supports the importance of an HFE-independent
IL-6-hepcidin axis in the development of hypoferremia and
anemia of inflammation; and ii) suggests that chronic
inflammation protects patients with HFE-related heredi-
tary hemochromatosis from iron accumulation.
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marked IgG type-κ monoclonal gammopathy of 21 g/L.
Under the suspicion of malignant lymphoma, a splenec-
tomy was performed with biopsy of liver and intra-
abdominal lymph nodes. No malignancy could be
detected. Unexpectedly, on histology spleen and liver
showed signs of hemosiderosis. More specifically, in the
absence of fibrosis and cirrhosis, Perls’ stain was gener-
alized and strongly positive in hepatocytes and also
present in some foci of Kupffer cells. At that time ferritin
was 1540 µg/L (normal <280 µg/L) and the transferrin
saturation (TS) 45%. In the late 1990s, HFE-gene analy-
sis disclosed homozygosity for the C282Y mutation in
the patient and his brother. This confirmed  the diagno-
sis of HFE-related HH.
Over the following year, the patient was treated with
30 phlebotomies of 500 mL each to a final ferritin level
of 24 µg/L (TS of 9.8%). Because the original physical
complaints of arthralgia and periodic fever persisted,
prednisone was started in a maintenance dose of 15
mg/day. Nevertheless, there were various short-lasting
bouts of fever, arthralgia, red swollen eyes and auricles.
In the late 1990s progressive deafness developed. The
monoclonal gammopathy remained stable. From 1993
to 2007, the patient received a further 15 phlebotomies
of 500 mL each. Serum ferritin levels, TS and CRP in this
time interval, varied between 36 and 540 µg/L, 11.4 and
106%, and 26 and 81 mg/L, respectively. Although these
data appeared to be too incomplete to draw conclusions
about a temporal relationship between inflammation
episodes and iron parameters, it is clear that the patient
was not always in an inflammatory state. 
In 2007, at the age of 52 years, the physical complaints
became progressively worse, and consisted of malaise,
arthralgia, chills, fever, and short lasting generalized
urticae. Clinical re-evaluation in 2008 showed, in spite
of the invariably high (20-25 g/L) monoclonal gammopa-
thy and high number (10-15%) of bone-marrow plasma
cells, no other signs of malignant multiple myeloma.
The bouts of fever were accompanied by IL-6 peaks fol-
lowed by increased hepcidin-concentrations (Figure 1,
panels A and B).
Based on the occurrence of chills with spiking fever
and urticae in the presence of IgG-κ gammopathy, the
diagnosis of variant Schnitzler’s syndrome was consid-
ered and it was decided to treat the patient with inter-
leukin-1 receptor antagonist (IL-1ra; anakinra; 1st dose
300 mg i.v., followed by six days 100 mg s.c.).11,12 Serum
ferritin levels were around 200 µg/L in the days before
treatment, stayed between 200 and 250 µg/L during
treatment and decreased thereafter to 140, 80 and 22
µg/L, at days 13, 17 and 36, respectively. Immediately
after the start of IL-1ra all complaints disappeared. The
treatment abrogated c.q. prevented the pattern of peak-
ing fever in the following days and IL-6 and CRP nor-
malized (Figure 1, panel A). Interestingly, serum hep-
cidin, clearly detectable in spite of the HFE-gene defect
during the febrile inflammatory episode, decreased rap-
idly after start of IL-1ra whereas serum iron increased
(Figure 1, panels B and C). IL-1β levels remained below
20 pg/mL before and after IL-1ra treatment (data not
shown). The moderately increased IL-18 levels were not
clearly affected by IL-1ra treatment (data not shown).
Figure 1. Laboratory measurements before and after treatment.
Body temperature, CRP and IL-6 levels (panel A), serum hepcidin
(panel B), iron and transferrin saturation (panel C) were measured
in an iron deplete C282Y homozygous patient with an auto-inflam-
matory condition, i.e. variant Schnitzler’s syndrome, before, during
and after treatment with the potent anti-inflammatory cytokine
interleukin-1 receptor antagonist (IL-1ra, anakinra). The period of
IL-1ra treatment is indicated in grey. 
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Design and Methods
Serum iron parameters and CRP were determined by
standard laboratory analysis. Cytokines and hepcidin
were assayed in one run in serum stored at -80°C.
Cytokines were measured using a multiplex Luminex
assay.13 Hepcidin was measured as described previous-
ly.14 Lower limit of detection was 0.5 nmol/L. Hepcidin
range in healthy volunteers (n=24) 0.5-13.9 nmol/L,
median 4.2 nmol/L; in untreated C282Y homozygotes
(n=22) <0.5-4.8 nmol/L, median 1.9 nmol/L; in C282Y
homozygotes (n=4) in maintenance phase of phleboto-
my (15 samples) <0.5-2.5 nmol/L.7 The study was car-
ried out in accordance with applicable Dutch regula-
tions concerning IRB review and informed consent. 
Results and Discussion
We describe the first human in vivo observation of
serum iron parameters, including hepcidin, in a patient
with an aberrant HFE-protein and inflammation, before
and after anti-inflammatory treatment. The patient pre-
sented with a combination of Schnitzler’s syndrome
and C282Y homozygosity of the HFE-gene under a
regime of maintenance phlebotomies, and was subse-
quently treated with anti-inflammatory anti-IL-1ra.
Schnitzler’s syndrome is a rare disabling auto-inflam-
matory disease. It is characterized by varying degrees of
recurrent bouts of unexplained fever, arthralgia or
arthritis, bone pain, lymphadenopathy, hepato- or
splenomegaly, leukocytosis, and elevated erythrocyte
sedimentation rate accompanied by an urticarial rash in
the presence of a monoclononal IgG or IgM gammopa-
thy. The complaints respond well to treatment with IL-
1ra.12
A biochemically penetrating C282Y homozygous
patient  is typically characterized by elevations of both
serum ferritin and serum iron levels.15 In the patient pre-
sented herein the ongoing and periodically exacerbating
inflammation increased serum ferritin levels and low-
ered TS, at times leading to a pattern of serum iron
indices less pathognomonic for HH. Thus, the iron sta-
tus in the patient might  be understood from a combi-
nation of HH treated with phlebotomies, and both
sequestering of iron in the reticulo-endothelial (RE)
macrophages and reduced intestinal iron uptake due to
inflammation induced elevated hepcidin levels.
The bouts of fever and IL-6 peaks in the patient were
followed by peaks of serum hepcidin. Hepcidin serum
concentrations before treatment in our patient ranged
from 2.9 to 11.2 nmol/L, high for an C282Y homozy-
gote in the maintenance phase of phlebotomy.7
Normalization of IL-6, triggered by IL-1ra treatment, led
to undetectable hepcidin and higher serum iron levels.
These findings confirm the (temporal) relations,
observed by us in an in vivo model of LPS induced
inflammation,6 and by Kawabata et al. in an IL-6 over-
producing patient with multicentric Castleman’s disease
treated with IL-6 receptor antibodies.16 In addition to
this, IL-1ra may directly inhibit IL-1 dependent hepcidin
production through the blockade of the IL-1 receptor.5
At first glance, our data seem to contrast with the
observation that in C282Y homozygotes the total body
iron does not correlate with the momentary IL-6 and
CRP levels.17 The latter report however can be criticized
because of the different kinetics of IL-6, CRP and body
iron. On the other hand, our observations of a patient
with a defect of the HFE protein that can still respond to
inflammatory stimuli by increasing hepcidin levels are
in agreement to those described for patients with defi-
ciency of the TfR2 protein.18 Interestingly, HFE and
TfR2 proteins have been found to interact in a common
signal transduction pathway to hepcidin.19
From our observation it is clear that C282Y homozy-
gosity and/or iron deficient anemia do not abrogate
cytokine induced hepcidin production. However, in the
absence of appropriate controls for this natural biologi-
cal model as provided by the described patient, no con-
clusions can be made as to whether the level achieved
in the patient is of the same level seen in humans with-
out HFE-related HH. Nevertheless, the retained ability
of C282Y homozygotes to increase hepcidin production
upon inflammatory stimuli, and thus, according to the
hepcidin mode of action,20 to redistribute iron out of the
bloodstream into RE macrophages, might be advanta-
geous in the setting of infection by extracellular
pathogens, but on the other hand might also increase
hepatic damage through iron-induced mesenchymal
activation.21
In conclusion, our in vivo human model of a C282Y
homozygous patient with an auto-inflammatory dis-
ease treated with IL-1ra supports the importance of an
HFE-independent cytokine-hepcidin axis in the devel-
opment of hypoferremia and anemia of inflammation.
These findings on the cross-talk between pathways reg-
ulating hepcidin provides indirect information on the
iron availability to certain pathogens relevant in critical
host defense strategies.2,22-24 It furthermore suggests that
chronic inflammation may reduce iron stores in C282Y
homozygotes, contributing to the variable penetrance
of the C282Y mutation.
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